HER2 Gene Mutation

Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas

Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer

Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung Cancer

HEAT Trial (HER2 Antibody Therapy With Lutetium-177)

A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer

Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients

Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Colorectal Cancer

ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors

Neratinib and Trastuzumab Biosimilar in Patients with HER2 Mutated Advanced Solid Cancers

Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct Adenocarcinoma

IAH0968 in Combination With GC for the Treatment of HER2-Positive Unresectable Advanced/Metastatic Malignant Tumors

To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Metastatic Colorectal Cancer

Her2-positive Lung Cancer Treated With Dedicated Drug

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor

Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001)

Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer